3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
228
Neoplasm Metastasis
17
Breast Neoplasms, Male
7
Breast Diseases
7
Neoplasms
6
Carcinoma, Intraductal, Noninfiltrating
4
Recurrence
3
Obesity
3
Breast Carcinoma In Situ
3
Breast Cancer Metastatic
3
Advanced Breast Cancer
3
Neoplasms by Site
2
Bulbo-Spinal Atrophy, X-Linked
2
Arthralgia
2
Vitamin D Deficiency
1
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Triple Negative Breast Neoplasms
1
Thoracic Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sleep Wake Disorders
1
Skin Diseases
1
Sexual Dysfunctions, Psychological
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Primary Breast Cancer ER+ve
1
Premenopausal Breast Cancer
1
Post Menopausal Women With Early Breast Cancer
1
Patient Acceptance of Health Care
1
Pain
1
Interventions
trametinib
1
talimogene laherparepvec
1
spartalizumab
1
pembrolizumab
1
nazartinib
1
exemestane
1
canakinumab
1
Telomerase
1
Tamoxifen
1
Surgical Procedures, Operative
1
Sentinel Lymph Node Biopsy
1
Pemetrexed
1
Paclitaxel
1
Mastectomy, Subcutaneous
1
Mastectomy, Segmental
1
Mammaplasty
1
Brachytherapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Ductal
×
exemestane
×
Breast
×
Clear all
NCT07499999
2026-03-30
BabyTEARS
Dana-Farber Cancer Institute
Phase 2
Not yet recruiting
140 enrolled